Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.
The company said its offer received acceptances from nearly 95 percent of Exiqon shareholders, and it expects to close the deal by June 28.
Qiagen has again extended the offer period and has reduced the acceptance threshold for share capital and voting rights.
Qiagen will hold a greater than 90 percent stake in Exiqon if members of Exiqon's management convert warrants they hold to shares rather than to cash.
In March, Qiagen announced that it had made a roughly $100 million offer for Exiqon in an effort to expand its presence in the RNA analysis field.
Product revenues were up slightly due to the firm's entry into new markets, while services revenues tumbled due to market fluctuations.
Qiagen has submitted an offer to buy all of Exiqon's shares for DKK18 each, for a total aggregate purchase price of DKK683 million ($103.5 million).
The firm's product revenues grew 29 percent year over year to DKK 24.7 million, and it is launching a new online sales platform next month.
Cancer researcher Alan Rabson has died at 92, the New York Times reports.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.